Written by The Anti-VEGF Market is expanding as the prevalence of retinal disorders increases and healthcare providers adopt advanced therapies for vision-threatening conditions. According to a recent report by Market Research Future, the global market was valued at approximately USD 25.98 billion in 2024 and is projected to reach USD 41.3 billion by 2035, registering a CAGR of 4.3% during 2025–2035.
Anti-VEGF therapies are primarily used for conditions such as age-related macular degeneration, diabetic retinopathy, macular edema, and retinal vein occlusion. According to a recent report by Market Research Future, the rising incidence of retinal diseases, particularly among aging populations and people living with diabetes, is a major factor supporting market expansion. Increased awareness, improved screening, and greater access to ophthalmic treatment are also contributing to demand.
The market includes products such as Eylea, Lucentis, and Beovu. Eylea currently represents the leading product segment, supported by its established clinical use and adoption in several retinal conditions. At the same time, the emergence of biosimilars is increasing competition and may improve treatment accessibility by creating additional therapeutic options.
Technological advancement is another important factor shaping the Anti-VEGF Market. Pharmaceutical companies are developing longer-acting formulations, improved drug-delivery approaches, and treatment strategies designed to reduce administration frequency. These innovations may help address the treatment burden associated with repeated intravitreal injections.
North America currently represents the largest regional market, accounting for more than 45% of global revenue in 2024. Asia-Pacific is also expected to demonstrate strong expansion as healthcare infrastructure improves, awareness of retinal diseases increases, and access to advanced ophthalmic therapies grows.
The future Growth outlook for the Anti-VEGF Market remains positive. Rising retinal disease prevalence, biosimilar development, personalized treatment approaches, increasing healthcare expenditure, and advances in drug delivery are expected to create further opportunities through 2035.
FAQs
1. What is the Anti-VEGF Market?
It covers medicines and related therapies that inhibit vascular endothelial growth factor and are used to manage several retinal diseases.
2. What is driving the Anti-VEGF Market?
Increasing retinal diseases, aging populations, diabetes-related eye complications, improved diagnosis, and advances in ophthalmic therapies are major drivers.
3. What are the major Anti-VEGF products?
Eylea, Lucentis, and Beovu are among the major products identified in the market.
4. What is the projected market size by 2035?
Market Research Future projects the global Anti-VEGF Market to reach approximately USD 41.3 billion by 2035.